Highlights of weekly biotech stock moves

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.15 (24%) to $0.78 on Tuesday after FDA's Psychopharmacologic Drugs Advisory Committee voted 9-8, with one abstention, in favor of recommending approval of inhaled Adasuve loxapine to treat agitation in patients with schizophrenia or bipolar disorder.

Alexza shares fell back to close at $0.66, up $0.04 on the week, and remains off $0.33 (33%) from its close of $0.99 on Dec. 7, before FDA reviewers said in briefing documents that Adasuve poses a "significant" risk of bronchospasm, particularly in patients with preexisting airway disease (see B12)...